Anchordx
2 known investors
AnchorDx (基准医疗) develops ctDNA methylation high-throughput sequencing technology for early cancer detection, using blood and urine samples to cover more than 70% of high-incidence cancers including lung, breast, digestive-system and urinary-system cancers. Its products span cancer early screening, early diagnosis, recurrence monitoring, and companion diagnostics.
BiotechDigital HealthHealthtech
Investors · 2
Frequently asked questions
- What does Anchordx do?
- AnchorDx (基准医疗) develops ctDNA methylation high-throughput sequencing technology for early cancer detection, using blood and urine samples to cover more than 70% of high-incidence cancers including lung, breast, digestive-system and urinary-system cancers. Its products span cancer early screening, early diagnosis, recurrence monitoring, and companion diagnostics.
- Who are Anchordx's investors?
- Anchordx's investors include Marathon Venture Partners, OrbiMed.